Appointment of Non-Executive Director

Appointment of Non-Executive Director

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that Kristof Neirynck, a highly experienced consumer brands executive, will join the Group on 1 December 2021 as an independent Non-Executive Director.

Kristof is currently Group Vice-President and Chief Marketing Officer Global Brands at Walgreens-Boots-Alliance (WBA), a global leader in retail pharmacy. He brings almost 20 years of international consumer brand experience including complex omni-channel business models, direct-to-consumer strategies and cross border e-commerce into China.

Kristof started his career in 2002 at Procter & Gamble in Belgium before moving to Procter & Gamble International in Switzerland in 2004 and working there for 11 years. He joined WBA in 2015 as Vice-President & Global Category Director Skin Care before being appointed to his current role in 2017. In this role, he has global responsibility for the portfolio of more than 20 WBA-owned brands across Beauty and Consumer Healthcare, representing more than $4bn in sales.

Following the departure of Nigel Clifford, who left the Group on 30 April 2021, Kristof’s appointment brings the number of independent Non-Executive Directors back to four.

David Cook, Alliance Pharma’s Chairman, said: “I am delighted to confirm the appointment of Kristof as a Non-Executive Director of Alliance and we look forward to his joining the Group on 1 December this year. Kristof brings outstanding operational and strategic experience of the consumer healthcare market, gained at global businesses. His international, omni-channel and marketing experience is highly complementary to the skillset of the existing Board members as we focus on the Group’s international expansion.”

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Kristof Leon Neirynck (43 years of age) has not been a director or partner of any companies during the five years preceding the date of this announcement. There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

For further information: